Clarus Ventures Promotes Scott Requadt To Managing Director

CAMBRIDGE, Mass. and FOSTER CITY, Calif., Jan. 6, 2015 /PRNewswire/ -- Clarus Ventures, a leading life science investment firm, announced today the promotion of Scott Requadt to Managing Director.

Scott joined the firm as a Principal at Clarus' Cambridge office in 2005, and was promoted to Partner in 2010.  He has led or co-led several Clarus investments, including TYRX, Intercept and Edev, as well as the acquisitions of royalty interests in Lexiscan® and Imbruvica®.  He is currently a Director of Edev, was a Director of TYRX (acquired by Medtronic), and has been a Board Observer on several other Clarus investments.  Scott joined Clarus from TransForm Pharmaceuticals where he was responsible for business development, corporate development and legal activities.  Prior to TransForm, Scott was an M&A attorney at Davis Polk & Wardwell. He holds a B.Com (Economics & Finance) from McGill University, a law degree from University of Toronto, and an MBA from Harvard Business School, where he was a Baker Scholar.

"This promotion recognizes Scott's many contributions over the past decade, as well as his leadership abilities for the future growth of our firm," said Nicholas Galakatos, Managing Director and a co-founder of Clarus Ventures.

"Scott's success in structuring and executing on innovative risk-sharing partnerships with pharma partners has been a key value creator for our firm," added Nicholas Simon, Managing Director and a co-founder of Clarus Ventures.

"I'm excited to continue to work with the terrific team at Clarus as we continue to invest the Clarus Funds," noted Scott Requadt.

About Clarus Ventures
Clarus Ventures is a leading global investment firm dedicated to life sciences. Founded in 2005 by a team of accomplished investment and operating professionals, Clarus manages over $1.6 billion invested in more than 50 private and public companies in biotechnology, medical devices and diagnostics. In every investment, Clarus employs a hands-on philosophy and adheres to investment principles that are founded on core competencies in drug development, complex partnership structuring and the ability to adapt to an ever-changing investment landscape. Clarus strives to generate outstanding returns for its investors by identifying and financing innovative medicines that improve people's lives. Clarus has offices in Cambridge, MA, and Foster City, CA. For more information please visit, www.clarusventures.com.

Contact: Lena Evans, Russo Partners, LLC, (212) 845-4262, [email protected]

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/clarus-ventures-promotes-scott-requadt-to-managing-director-300015946.html

SOURCE Clarus Ventures, LLC

Suggested Articles

As Relay looks to enter the clinic in 2020, the company is adding a trio of biopharma vets to its leadership team.

A phase 3 trial of Myovant Sciences’ relugolix in prostate cancer has met its primary endpoint, teeing the company up to file for FDA approval.

The Medicines Company, fresh from its turn at the AHA this weekend, has seen its shares jump on growing rumors that Novartis wants to acquire it.